Literature DB >> 9808668

Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human.

R Kawai1, D Mathew, C Tanaka, M Rowland.   

Abstract

The tissue distribution kinetics of i.v. Cyclosporine A (CyA) was investigated extensively in rats. The concentration-to-time data of 11 organs were analyzed separately using local physiologically based pharmacokinetic models, involving nonlinear plasma-to-blood cell distribution, membrane-permeability-limited plasma-to-tissue distribution and either linear or nonlinear tissue binding. Two global physiologically based pharmacokinetic models were then evaluated, each comprising arterial and venous pools together with the 11 organs, adopting either of the two local models. Both global models successfully described the blood and tissue distribution kinetics of CyA. In nonlinear model, the estimated dissociation constants (Kd) for the intracellular saturable binding ranged 0.2 to 60 ng/ml among the organs, which are comparable with values reported for cyclophilin-CyA binding in vitro. The predicted human pharmacokinetic profile using the physiologically based pharmacokinetic models, after scale-up of physiological parameters from rat to human, generally agreed with the observations following i.v. and oral administration, with moderate discrepancies due presumably to uncharacterized species differences and/or the effect of i.v. vehicle on the CyA binding in plasma. Nevertheless, the models allow reasonable prediction of drug exposure at the biological target, i.e., intracellular, unbound CyA, which may differ among various organs according to the local physiological elements, e.g., tissue cellular membrane permeability. As well as helping optimize the CyA regimen in patients, who are likely to exhibit a variety of physiological and pathological conditions, the modeling suggests possible insights into the known grafted-organ specific efficacy of CyA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808668

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  53 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Use of dried blood spots in drug development: pharmacokinetic considerations.

Authors:  Malcolm Rowland; Gary T Emmons
Journal:  AAPS J       Date:  2010-04-10       Impact factor: 4.009

Review 3.  Prediction of exposure-response relationships to support first-in-human study design.

Authors:  John P Gibbs
Journal:  AAPS J       Date:  2010-10-22       Impact factor: 4.009

Review 4.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

5.  A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.

Authors:  Anthe S Zandvliet; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-09-01       Impact factor: 2.745

6.  Physiologically based pharmacokinetic modelling: a sub-compartmentalized model of tissue distribution.

Authors:  Max von Kleist; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-09-25       Impact factor: 2.745

7.  Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat.

Authors:  Ken-ichi Umehara; Gian Camenisch
Journal:  Pharm Res       Date:  2011-10-20       Impact factor: 4.200

Review 8.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

Review 10.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.